PHARMACOKINETIC AND CLINICAL EVALUATION OF AZITHROMYCIN IN THE PEDIATRIC FIELD
1997 Volume 50 Issue 2 Pages 206-214
Details
1997 Volume 50 Issue 2 Pages 206-214
35 children between 9 months and 12 years of ages were gi ven 9.1 to 12.2 mg/kg of azithromycin (AZM) once a day for 3 days. In the treatment of pediatric infectious diseases, we studied pharmacokinetics, efficacy and safetiness of AZM. After administration of 10 mg/kg/day of AZM for 3 days, the elimination half-life was calculated to be 38.2±1 16.3 hours (n= 6, mean±S. D.). The excretion rate of AZM in the urine within 120 hours of administration was 9.0±2.3% (n= 5). For the evaluation of efficacy of AZM, we treated 33 cases of children with pharyngotonsillitis, bronchitis, mycoplasma bronchitis, pneumonia, mycoplasma pneumonia, atypical pneumonia, and SSTI. The efficacy rate of these cases were 93.9%. 6 strains of bacteria were identified as causative agents. All strains were eradicated upon the treatment. One case of elevated GOT and GPT and two cases of elevated GPT were observed. No clinical adverse reactions were observed.
In conclusion, AZM was useful for the treatment of pediatric infectious diseases we examined.
